Protara Therapeutics, Inc. APIC, Share-based Payment Arrangement, Restricted Stock Unit, Increase for Cost Recognition
Protara Therapeutics, Inc. (TARA) reported APIC, Share-based Payment Arrangement, Restricted Stock Unit, Increase for Cost Recognition of $294.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Shareholders' Equity › APIC, Share-Based Payment Arrangement, Increase for Cost Recognition
us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition · last filed 2026-08-11
- Protara Therapeutics, Inc. apic, share-based payment arrangement, restricted stock unit, increase for cost recognition for the quarter ending 2026-06-30 was $294.00K, a 76.05% increase year-over-year.
- Protara Therapeutics, Inc. apic, share-based payment arrangement, restricted stock unit, increase for cost recognition for the quarter ending 2026-03-31 was $317.00K, a 161.98% increase year-over-year.
- Protara Therapeutics, Inc. apic, share-based payment arrangement, restricted stock unit, increase for cost recognition for the quarter ending 2025-09-30 was $196.00K, a 79.82% increase year-over-year.
- Protara Therapeutics, Inc. apic, share-based payment arrangement, restricted stock unit, increase for cost recognition for the quarter ending 2025-06-30 was $167.00K, a 50.45% increase year-over-year.
- Protara Therapeutics, Inc. apic, share-based payment arrangement, restricted stock unit, increase for cost recognition for fiscal 2025 was $685.00K, a 42.71% increase from fiscal 2024.
- Protara Therapeutics, Inc. apic, share-based payment arrangement, restricted stock unit, increase for cost recognition for fiscal 2024 was $480.00K, a 60.26% decline from fiscal 2023.
- Protara Therapeutics, Inc. apic, share-based payment arrangement, restricted stock unit, increase for cost recognition for fiscal 2023 was $1.21M.
| Period end | APIC, Share-based Payment Arrangement, Restricted Stock Unit, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Restricted Stock Unit, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Restricted Stock Unit, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Restricted Stock Unit, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2026-06-30 | $294.00K 10-Q · filed 2026-08-11 | $611.00K derived: sum of 2 quarters · filed 2026-08-11 | ||
| 2026-03-31 | $317.00K 10-Q · filed 2026-08-11 | |||
| 2025-12-31 | $685.00K 10-K · filed 2026-03-10 | |||
| 2025-09-30 | $196.00K 10-Q · filed 2025-11-10 | $363.00K derived: sum of 2 quarters · filed 2026-08-11 | $484.00K derived: sum of 3 quarters · filed 2026-08-11 | |
| 2025-06-30 | $167.00K 10-Q · filed 2026-08-11 | $288.00K derived: sum of 2 quarters · filed 2026-08-11 | ||
| 2025-03-31 | $121.00K 10-Q · filed 2026-08-11 | |||
| 2024-12-31 | $480.00K 10-K · filed 2026-03-10 | |||
| 2024-09-30 | $109.00K 10-Q · filed 2025-11-10 | $220.00K derived: sum of 2 quarters · filed 2025-11-10 | $371.00K derived: sum of 3 quarters · filed 2025-11-10 | |
| 2024-06-30 | $111.00K 10-Q · filed 2025-11-10 | $262.00K derived: sum of 2 quarters · filed 2025-11-10 | ||
| 2024-03-31 | $151.00K 10-Q · filed 2025-11-10 | |||
| 2023-12-31 | $1.21M 10-K · filed 2025-03-05 | |||
| 2023-09-30 | $275.00K 10-Q · filed 2024-11-12 | $601.00K derived: sum of 2 quarters · filed 2024-11-12 | $915.00K derived: sum of 3 quarters · filed 2024-11-12 | |
| 2023-06-30 | $326.00K 10-Q · filed 2024-11-12 | $640.00K derived: sum of 2 quarters · filed 2024-11-12 | ||
| 2023-03-31 | $314.00K 10-Q · filed 2024-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |